All patients, aged 鈮 21, underwent 鈮 1 full cycle of EPD or ERD post-ASCT, administered for a total of four 28-day cycles, following the standard dosing regimen with a rapid dexamethasone taper over the last two cycles.Results:A total of 78 HR MM pts, median age 64 years with 51.2...
Mikhael concluded by saying that “nearly all” patients with multiple myeloma should receive maintenance therapy with lenalidomide after ASCT. “Maintenance therapy in myeloma further adds to a recent evidence-based trend to increase the intensity of therapies before ASCT, continue the prolific use of...
Post‐ASCT, the incidence of neurotoxicity makes bortezomib less attractive for maintenance, but a limited duration of consolidation may be beneficial. The benefits of consolidation with bortezomib monotherapy have been explored using differing protocols and cumulative doses (Sonneveld etal, 2012; Mellq...
Conclusion: in pts with intermediate-risk de-novo AML and FLT3-ITD genotype or WT NPM1 and CEBPA without FLT3-ITD, a RIC ASCT as post-remission therapy improves the PFS as compared to conventional chemotherapy, demonstrating a potent graft-versus-leukemia effect in these pts with AML at a ...
Belamaf had no apparent impact on stem cell collection (median 9.3x106 CD34+/kg in median 2 days) or post-ASCT engraftment (median time to ANC>1000 and platelets>50 of 11 and 15 days, respectively). Seventeen subjects have reached the D+90 response assessment; all were able to start ...
explore the safety, immune, and clinical activity of immunotherapy based on the “mixed” GVAX platform (autologous leukemia cells mixed with GM-CSF–secreting K562 cells CG9962 or K562/GM) combined with ASCT and the adoptive transfer of immunotherapy-primed lymphocytes as postremission therapy for...
Post‐ASCT, the incidence of neurotoxicity makes bortezomib less attractive for maintenance, but a limited duration of consolidation may be beneficial. The benefits of consolidation with bortezomib monotherapy have been explored using differing protocols and cumulative doses (Sonneveld etal, 2012; Mellq...
Luciano J. Costa, MD, PhD, discusses data on the use of minimal residual disease responses to modulate quadruplet induction therapy following autologous stem cell transplant in newly diagnosed multiple myeloma.
Thus, it has been postulated that post-ASCT consolidative immunotherapy might eradicate minimal residual disease, based on antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism, and have a favorable impact on relapse rate and even OS. This view has led to a considerable interest in ...
Post ASCT engraftment syndrome (ES) is a well-known clinical complication, however many aspects of its etiology, treatment and outcomes remain largely controversial. In this retrospective study, we hypothesized that ES is frequent, and empiric treatment of presumed ES with steroids improves patient ...